Law360, New York (July 02, 2007, 12:00 AM ET) -- Kali Laboratories Inc. will not be able to introduce a generic version of a Valeant Pharmaceuticals International epileptic seizure treatment for more than three years under a patent infringement settlement announced Monday.
Under the agreement, Kali may not introduce a generic version of Diastate and Diastate AcuDial until September 2010. Other terms of the settlement, which was reached last week at a conference in a New Jersey court, were not disclosed. The companies have 60 days to finalize the agreement.
Xcel Pharmaceuticals, which was acquired by...
Drug Makers Settle Suit Over Epilepsy Treatment
To view the full article, take a free trial now.
